Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Mar;67(3):560–563. doi: 10.1038/bjc.1993.102

Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate.

N P O'Rourke 1, E V McCloskey 1, S Vasikaran 1, K Eyres 1, D Fern 1, J A Kanis 1
PMCID: PMC1968276  PMID: 8439504

Abstract

Thirty patients with hypercalcaemia due to malignancy that persisted following rehydration, were treated with a single dose of the bisphosphonate, clodronate. Clodronate (1.5 g) was administered intravenously in 500 ml normal saline over 4 h. Serum and urine biochemistry were measured before and after treatment and the results were compared with data from 15 patients given the recommended regimen 300 mg intravenous clodronate daily for 5 consecutive days. The single infusion induced a rapid and significant fall in serum calcium, apparent at day 3 (P < 0.0001) that persisted to the end of follow-up at day 10 (P < 0.001). Eighty per cent (24/30) of patients became normocalcaemic. The response was associated with a significant decrease in fasting urinary calcium excretion, and no change in renal function, as judged by serum creatinine. The same dose of clodronate, given as 5 daily infusions, induced a comparable decrease in serum calcium, but was less rapid in onset so that at day 3 the serum calcium was significantly lower with the single infusion (P = 0.02). The calcium lowering effect of both regimens depended on the tumour type. We conclude that the single infusion of 1500 mg clodronate is as effective in reducing serum calcium as the same dose given over 5 days. The single infusion has a more rapid onset of effect, is more convenient than multiple infusions, and has no adverse effect on renal function.

Full text

PDF
560

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bonjour J. P., Philippe J., Guelpa G., Bisetti A., Rizzoli R., Jung A., Rosini S., Kanis J. A. Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate. Bone. 1988;9(3):123–130. doi: 10.1016/8756-3282(88)90001-4. [DOI] [PubMed] [Google Scholar]
  2. Bonjour J. P., Rizzoli R. Pathophysiological aspects and therapeutic approaches of tumoral osteolysis and hypercalcemia. Recent Results Cancer Res. 1989;116:29–39. doi: 10.1007/978-3-642-83668-8_2. [DOI] [PubMed] [Google Scholar]
  3. Bonjour J. P., Rizzoli R. Treatment of hypercalcaemia of malignancy with clodronate. Bone. 1991;12 (Suppl 1):S19–S23. doi: 10.1016/8756-3282(91)90062-n. [DOI] [PubMed] [Google Scholar]
  4. Coleman R. E., Rubens R. D. 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer. Br J Cancer. 1987 Oct;56(4):465–469. doi: 10.1038/bjc.1987.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gallacher S. J., Ralston S. H., Patel U., Boyle I. T. Side-effects of pamidronate. Lancet. 1989 Jul 1;2(8653):42–43. doi: 10.1016/s0140-6736(89)90277-8. [DOI] [PubMed] [Google Scholar]
  6. Kanis J. A., McCloskey E. V., Paterson A. H. Use of diphosphonates in hypercalcaemia due to malignancy. Lancet. 1990 Jan 20;335(8682):170–171. [PubMed] [Google Scholar]
  7. Kanis J. A., Urwin G. H., Gray R. E., Beneton M. N., McCloskey E. V., Hamdy N. A., Murray S. A. Effects of intravenous etidronate disodium on skeletal and calcium metabolism. Am J Med. 1987 Feb 23;82(2A):55–70. doi: 10.1016/0002-9343(87)90488-8. [DOI] [PubMed] [Google Scholar]
  8. Kanis J. A., Yates A. J. Measuring serum calcium. Br Med J (Clin Res Ed) 1985 Mar 9;290(6470):728–729. doi: 10.1136/bmj.290.6470.728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Martin T. J., Ebeling P. R., Rodda C. P., Kemp B. E. Humoral hypercalcemia of malignancy: involvement of a novel hormone. Aust N Z J Med. 1988 May;18(3):287–295. doi: 10.1111/j.1445-5994.1988.tb02039.x. [DOI] [PubMed] [Google Scholar]
  10. Mundy G. R., Ibbotson K. J., D'Souza S. M., Simpson E. L., Jacobs J. W., Martin T. J. The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms. N Engl J Med. 1984 Jun 28;310(26):1718–1727. doi: 10.1056/NEJM198406283102607. [DOI] [PubMed] [Google Scholar]
  11. Percival R. C., Yates A. J., Gray R. E., Galloway J., Rogers K., Neal F. E., Kanis J. A. Mechanism of malignant hypercalcaemia in carcinoma of the breast. Br Med J (Clin Res Ed) 1985 Sep 21;291(6498):776–779. doi: 10.1136/bmj.291.6498.776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Preston C. J., Yates A. J., Beneton M. N., Russell R. G., Gray R. E., Smith R., Kanis J. A. Effective short term treatment of Paget's disease with oral etidronate. Br Med J (Clin Res Ed) 1986 Jan 11;292(6513):79–80. doi: 10.1136/bmj.292.6513.79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ralston S. H., Gallacher S. J., Patel U., Dryburgh F. J., Fraser W. D., Cowan R. A., Boyle I. T. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet. 1989 Nov 18;2(8673):1180–1182. doi: 10.1016/s0140-6736(89)91791-1. [DOI] [PubMed] [Google Scholar]
  14. Russell R. G., Smith R., Preston C., Walton R. J., Woods C. G. Diphosphonates in Paget's disease. Lancet. 1974 May 11;1(7863):894–898. doi: 10.1016/s0140-6736(74)90347-x. [DOI] [PubMed] [Google Scholar]
  15. Singer F. R., Ritch P. S., Lad T. E., Ringenberg Q. S., Schiller J. H., Recker R. R., Ryzen E. Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group. Arch Intern Med. 1991 Mar;151(3):471–476. [PubMed] [Google Scholar]
  16. Stewart A. F., Horst R., Deftos L. J., Cadman E. C., Lang R., Broadus A. E. Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. N Engl J Med. 1980 Dec 11;303(24):1377–1383. doi: 10.1056/NEJM198012113032401. [DOI] [PubMed] [Google Scholar]
  17. Thiébaud D., Leyvraz S., von Fliedner V., Perey L., Cornu P., Thiébaud S., Burckhardt P. Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer. 1991;27(1):37–41. doi: 10.1016/0277-5379(91)90056-j. [DOI] [PubMed] [Google Scholar]
  18. Urwin G. H., Yates A. J., Gray R. E., Hamdy N. A., McCloskey E. V., Preston F. E., Greaves M., Neil F. E., Kanis J. A. Treatment of the hypercalcaemia of malignancy with intravenous clodronate. Bone. 1987;8 (Suppl 1):S43–S51. [PubMed] [Google Scholar]
  19. Yates A. J., Gutierrez G. E., Smolens P., Travis P. S., Katz M. S., Aufdemorte T. B., Boyce B. F., Hymer T. K., Poser J. W., Mundy G. R. Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption, and bone metabolism in vivo and in vitro in rodents. J Clin Invest. 1988 Mar;81(3):932–938. doi: 10.1172/JCI113406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ziegler R., Scharla S. H. Treatment of tumor hypercalcemia with clodronate. Recent Results Cancer Res. 1989;116:46–53. doi: 10.1007/978-3-642-83668-8_4. [DOI] [PubMed] [Google Scholar]
  21. van Holten-Verzantvoort A. T., Bijvoet O. L., Cleton F. J., Hermans J., Kroon H. M., Harinck H. I., Vermey P., Elte J. W., Neijt J. P., Beex L. V. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet. 1987 Oct 31;2(8566):983–985. doi: 10.1016/s0140-6736(87)92555-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES